EGFR and non-small cell lung carcinoma: Based on the results of clinical trials, immunotherapy monotherapy has been approved as the first-line treatment for advanced epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) negative NSCLC patients with PD-L1 expression ≥50%, and for patients with PD-L1 expression < 50%, immunotherapy combined with chemotherapy and/or antiangiogenesis therapy can bring more survival benefits than chemotherapy [14–16].